THERAPEUTIC COMPOUNDS
The present disclosure provides methods of treating catecholaminergic polymorphic ventricular tachycardia, comprising administering a pharmaceutical composition comprising, in a unit dosage form, a therapeutically effective amount of 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-1(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically acceptable excipient.
1 . A method of treating catecholaminergic polymorphic ventricular tachycardia (CPVT), comprising administering to a subject in need thereof a therapeutically-effective amount of a compound that is 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid or a pharmaceutically-acceptable salt thereof, wherein the administering is once daily.
2 . The method of claim 1 , wherein the catecholaminergic polymorphic ventricular tachycardia is catecholaminergic polymorphic ventricular tachycardia type 1.
3 . The method of claim 2 , wherein the catecholaminergic polymorphic ventricular tachycardia type 1 is characterized by a mutation in a Ryanodine Receptor 2 gene.
4 . The method of claim 3 , wherein the mutation in the Ryanodine Receptor 2 gene is an autosomal dominant mutation.
5 . The method of claim 1 , wherein the subject is undergoing a treatment regimen for CPVT, wherein the treatment regimen for CPVT comprises a beta-blocker.
6 . (canceled)
7 . The method of claim 1 , wherein the subject is undergoing a treatment regimen for CPVT, wherein the treatment regimen for CPVT comprises a sodium channel inhibitor.
8 . The method of claim 7 , wherein the sodium channel inhibitor is flecainide or a pharmaceutically-acceptable salt thereof.
9 . (canceled)
10 . The method of claim 1 , wherein the treating the catecholaminergic polymorphic ventricular tachycardia (CPVT) reduces a likelihood of developing ectopy in the subject.
11 - 19 . (canceled)
20 . The method of claim 1 , wherein the treating the catecholaminergic polymorphic ventricular tachycardia (CPVT) reduces a likelihood of sudden cardiac death in the subject.
21 - 28 . (canceled)
29 . The method of claim 1 , wherein the compound or pharmaceutically-acceptable salt thereof is a hemifumarate salt.
30 - 43 . (canceled)
44 . The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is administered to the subject as a pharmaceutical composition in unit dosage form, wherein the unit dosage form further comprises a pharmaceutically acceptable excipient.
45 - 47 . (canceled)
48 . The method of claim 44 , wherein the unit dosage form comprises an amount of 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate equivalent to about 20 to about 200 mg of 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid.
49 - 57 . (canceled)
58 . The method of claim 44 , wherein the unit dosage form is a gastro-resistant tablet.
59 - 76 . (canceled)
77 . The method of claim 1 , further comprising administering to the subject a beta-blocker.
78 . (canceled)
79 . The method of claim 77 , wherein the beta-blocker is administered in a reduced amount, wherein the reduced amount is about less than an amount used to treat CPVT in the subject in absence of the compound.
80 . The method of claim 77 , wherein the beta-blocker is a non-selective beta-blocker.
81 . The method of claim 1 , further comprising administering to the subject a sodium channel inhibitor.
82 . The method of claim 81 , wherein the sodium channel inhibitor is flecainide or a pharmaceutically-acceptable salt thereof.
83 . (canceled)
84 . The method of claim 81 , wherein the sodium channel inhibitor is administered in a reduced amount, wherein the reduced amount is about less than an amount used to treat CPVT in the subject in the absence of the compound.
85 - 91 . (canceled)
92 . A pharmaceutical composition comprising in a unit dosage form 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid or a pharmaceutically-acceptable salt thereof, wherein in a controlled study, if the unit dosage form is administered to a study subject, then an accumulation ratio for AUC of 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid or the pharmaceutically-acceptable salt thereof or a pharmaceutically-acceptable ion thereof between about 1.4 and about 1.8 is present in the subject, wherein the controlled study comprises:
(a) orally administering the pharmaceutical composition in unit dosage form to the study subject;
(b) after the administering, collecting blood samples from the study subject at one or more time points after the administering; and
(c) measuring a plasma concentration of 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid or an ionized form thereof in the blood samples,
wherein the accumulation ratio for AUC is calculated as a ratio of AUC 0-24 at steady state/AUC 0-24 Day 1,
wherein:
AUC is area under the concentration-time curve; and
AUC 0-24 is area under the concentration-time curve, from time 0 to 24 hours post-dose.